Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Clinical trial NCT06846606 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06846606
Sponsor: Auron Therapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AML Relapsed Myelodysplastic Syndromes Refractory Myelodysplastic Syndromes Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Start date: 2025-05-01
Primary completion: 2027-04-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.